EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid ( UDCA) in Parkinson's Disease

Thomas Payne, Matthew Appleby, Ellen Buckley, Linda M A van Gelder, Benjamin H Mullish iD, Matilde Sassani, Mark J Dunning, Dena Hernandez, Sonja W Scholz iD, Alisdair McNeill, Vincenzo Libri, Sarah Moll und 7 weitere

Movement Disorders · 2023-08 · 38 (8) · 1493-1502

DOI: 10.1002/mds.29450 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 29.05.2023. Verfasst von Thomas Payne und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, Department of Health, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across a range of preclinical in vitro and in vivo models of PD.

Objectives

To investigate the safety and tolerability of high‐dose UDCA in PD and determine midbrain target engagement.

Methods

The UP (UDCA in PD) study was a phase II, randomized, double‐blind, placebo‐controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The primary outcome was safety and tolerability. Secondary outcomes included 31‐phosphorus magnetic resonance spectroscopy ( 31 P‐MRS) to explore target engagement of UDCA in PD midbrain and assessment of motor progression, applying both the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS‐UPDRS‐III) and objective, motion sensor‐based quantification of gait impairment.

Results

UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain 31 P‐MRS demonstrated an increase in both Gibbs free energy and inorganic phosphate levels in the UDCA treatment group compared to placebo, reflecting improved ATP hydrolysis. Sensor‐based gait analysis indicated a possible improvement of cadence (steps per minute) and other gait parameters in the UDCA group compared to placebo. In contrast, subjective assessment applying the MDS‐UPDRS‐III failed to detect a difference between treatment groups.

Conclusions

High‐dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease‐modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansUrsodeoxycholic AcidDouble-Blind Method

Stichwörter der Autor:innen

31P-MR spectroscopyUDCAneuroprotectionsupervised gait analysisursodeoxycholic acid

Substanzen

Ursodeoxycholic Acid

Autor:innen und Institutionen

  • Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
  • NIHR UCLH Clinical Research Facility-Leonard Wolfson Experimental Neurology Centre, National Hospital for Neurology & Neurosurgery, London, UK.
  • Department of Clinical and Movement Neurosciences, Institute of Neurology, University College London, London, UK.
  • Department of Mechanical Engineering and Insigneo Institute for In Silico Medicine, The University of Sheffield, Sheffield, UK.
  • Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, St Mary's Hospital Campus, Imperial College London, London, UK.
  • The Bioinformatics Core, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield, UK.

ORCID-Profile: Benjamin H Mullish, Sonja W Scholz, Thomas Foltynie, Oliver Bandmann

Förderung

  • Intramural NIH HHS
  • Department of Health
  • Medical Research Council
  • CPT
  • Jon Moulton Charity Trust

Zitieren

APA

Payne, T., Appleby, M., Buckley, E., van Gelder, L. M. A., Mullish, B. H., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S. W., McNeill, A., Libri, V., Moll, S., Marchesi, J. R., Taylor, R., Su, L., Mazzà, C., Jenkins, T. M., Foltynie, T., & Bandmann, O. (2023). A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid ( UDCA) in Parkinson's Disease. Movement Disorders, 38(8), 1493-1502. https://doi.org/10.1002/mds.29450

Vancouver

Payne T, Appleby M, Buckley E, van Gelder LMA, Mullish BH, Sassani M, et al. A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid ( UDCA) in Parkinson's Disease. Movement Disorders. 2023;38(8):1493-1502. doi:10.1002/mds.29450

BibTeX
@article{Payne2023,
  author = {Payne, Thomas and Appleby, Matthew and Buckley, Ellen and van Gelder, Linda M A and Mullish, Benjamin H and Sassani, Matilde and Dunning, Mark J and Hernandez, Dena and Scholz, Sonja W and McNeill, Alisdair and Libri, Vincenzo and Moll, Sarah and Marchesi, Julian R and Taylor, Rosie and Su, Li and Mazzà, Claudia and Jenkins, Thomas M and Foltynie, Thomas and Bandmann, Oliver},
  title = {A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid ( UDCA) in Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {8},
  pages = {1493--1502},
  doi = {10.1002/mds.29450}
}
Kostenlos starten →